# Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Study · id `cardio:ct-nct06822790` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06822790](<https://clinicaltrials.gov/study/NCT06822790>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06822790

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 710 participants.

## Technical summary

Registry record NCT06822790. Allocation not applicable; no masking; primary purpose treatment. Start 2025-04-09 (actual); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 710 participants (enrolled count; ClinicalTrials.gov record NCT06822790, source copy `cardio:ctgov-nct06822790-2026-10-01`, retrieved 2026-10-31)
- Started: 2025-04-09 (actual) (ClinicalTrials.gov record NCT06822790, source copy `cardio:ctgov-nct06822790-2026-10-01`, retrieved 2026-10-31)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT06822790, source copy `cardio:ctgov-nct06822790-2026-10-01`, retrieved 2026-10-31)
- Completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT06822790, source copy `cardio:ctgov-nct06822790-2026-10-01`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; China; Croatia; Czechia; France; Germany; Hungary; Italy; Japan; Latvia; Lithuania; New Zealand; Poland; Romania; Slovakia; South Africa; Spain; United Kingdom (ClinicalTrials.gov record NCT06822790, source copy `cardio:ctgov-nct06822790-2026-10-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06822790-2026-10-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- Acronym: SHASTA-10
- Condition: Hypertriglyceridemia
- Intervention (Drug): Plozasiran Injection
- Lead sponsor: Arrowhead Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Arrowhead Pharmaceuticals (`cardio:org-arrowhead-pharmaceuticals`)

## Provenance

Content hash: 6211ed7023b4b0c477726d36a8ec4b9bf8049a849e4b3e0ff3e9a9e2a6fd815e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
